Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 07/31/2006. OMB 0651-0031/ U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Application Number 10/718,077 **TRANSMITTAL** 11/20/03 Filing Date **FORM** First Named Inventor Corvari (to be used for all correspondence after initial filing) Art Unit 1617 **Examiner Name** T. Criares Total Number of Pages in This Submission CP185B 590 Attorney Docket Number ENCLOSURES (check all that apply) After Allowance Communication to Fee Transmittal Form Drawing(s) Technology Center (TC) Appeal Communication to Board of Fee Attached Licensing-related Papers Appeals and Interferences Petition Appeal Communication to TC Amendment / Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Terminal Disclaimer Other Enclosure(s) Extension of Time Request (please identify below): 1449 & 18 References Request for Refund Express Abandonment Request Copy of International Search CD, Number of CD(s) Report

Remarks

1.52 or 1.53	
	SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT
Firm or Individual name	Eric K. Voelk, Registration No. 45,185
Signature	E alle
Date	September 15, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name

Information Disclosure Statement

Certified Copy of Priority Document(s)

Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR

Maureen K. Fitzpatrick

Signature

September 15, 2004

Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 132 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Attorney Docket No.: CP185B PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: Dickason et al.

Serial No.: 10/718,077 Group Art Unit.: 1617

Filing Date: November 20, 2003 Examiner: T. Criares

For.: PARTICLE-FORMING COMPOSITIONS CONTAINING FUSED

PYRROLOCARBAZOLES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

DATE OF DEPOSIT: September 15, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE
INDICATED ABOVE AND IS ADDRESSED TO THE
COMMISSIONER FOR PATENTS, P.O. BOX 1450,

ALEXANDRIA, VA 22313-1450.

Maureen K. Fitzpartek

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F. R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as a representation that a search has been made or an admission that this information is material to the patentability as defined in 37 C.F.R. § 1.56(b).

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above-identified application as set forth in § 1.491, or before the mailing date of a first Office Action on the merits of the above-identified application. No additional fee is required.

A copy of each cited non-US patent reference is enclosed.

Please charge any deficiency or credit any overpayment to Deposit Account No. 03-1195.

Date: September 15, 2004

Attorney for Applicant Registration No. 45,185

CEPHALON, Inc. 145 Brandywine Parkway West Chester, PA 19380 Telephone: (610) 738-6465 Facsimile: (610) 738-6590

PE VOY & TRADELLE

FORM PTO-1449	Attorney Docket	CP185B	
INFORMATION DISCLOSURE	Application Number	10/718,077	
STATEMENT BY APPLICANT	Filing Date	11/20/03	
Victor Details and Dublications Cited by	First Named Inventor	Corvari	
List of Patent and Publications Cited by Applicant	Group Art Unit	1614	
F	Examiner Name	Unknown	
	Sheet	1 of 2	

			U.S. PA	TENT DOCU	JMENTS			
Examiner Initials	Cite No.	Document Number	Name		Date of Publication	Class	Subclass	
	A1	4,877,776	Murkata	et al.	10/31/1989			
	A2	4,923,986	Murkata	et al.	05/8/1990			
	A3	5,043,335	Kleinsc	hrothe et al.	08/27/1991			
	A4	5,093,330	Caravat	ti et al.	03/03/1992			
	A5	5,242,932	Gandy e	et al.	09/07/1993			
	A6	5,461,146	Lewis e	t al.	10/24/1995			
	A7	5,468,872	Glicksm	nan et al.	11/21/1995			
	A8	5,475,110	Hudkins	s et al.	12/12/1995			
	A9	5,516,771	Dionne	et al.	05/14/1996			
	A10	5,591,855	Hudkins		01/07/1997	-		
	A11	5,594,009	Hudkins		01/14/1997			
	A12	5,599,808	Goldste		02/04/1997			
	A13	5,616,724	Hudkins		04/01/1997			
	A14	5,621,100	Lewis e		04/15/1997			
	A15	5,621,101	Lewis e		04/15/1997			
	A16	5,658,898	Weder		08/19/1997			
	A17	5,705,511	Hudkins	s et al.	01/06/1998			
	A18	5,726,164	Weder		03/10/1998			
	A19	5,801,190	Hudkin		09/01/1998			
	A20	6,200,968	Dickaso		03/13/2001	-		
		FC	REIGN	PATENT DO	CUMENTS			
Examiner	Cite N	lo. Document	No.	Date	Country		Translation	
Initials						<u> </u>	YES 1	NO
	B1	0 657 16	4	06/14/1995	EP			
	B2	0 850 64	6	07/01/1998	EP			
	В3	JP 04-12	4122	04/24/1992	Japan			**
	B4	JP 62-12	0388	06/01/1987	Japan		abstract	
	B5	JP 62-15	5284	07/10/1987	Japan		abstract	
	B6	JP 62-15	5285	07/10/1987	Japan		abstract	
	B7	JP 63-29	5588	12/01/1988	Japan		Х	
	B8	JP 63-29	5589	12/01/1988	Japan		abstract	

Examiner's Signature	1111111	Date:	

^{**}A copy of the International Search Report dated 11/17/99 is attached which indicates the documents considered to be relevant and provides an explanation of the relevance of each reference.

FORM PTO-1449	Attorney Docket	CP185B
INFORMATION DISCLOSURE	Application Number	10/718,077
STATEMENT BY APPLICANT	Filing Date	11/20/03
The CD and TD III at the Country	First Named Inventor	Corvari
List of Patent and Publications Cited by Applicant	Group Art Unit	1614
· · · · · · · · · · · · · · · · · · ·	Examiner Name	Unknown
	Sheet	2 of 2

E	39	WO 00/48571	08/24/2000	WIPO	
E	310	WO 93/00909	01/21/1993	WIPO	
E	311	WO 93/08809	05/13/1993	WIPO	
E	312	WO 97/46565	12/11/1997	WIPO	

	ОТ	HER DOCUMENTS Non-Patent Literature Documents
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), Title of Article, Title of Journal (book, magazine, catalog, etc.) Date, Pertinent Pages, Volume-Issue Number, publisher, city and/or country where published.
	C1	Berg et al., "K-252a Inhibitis Nerve Growth Factor-induced trk Proto- oncogene Tyrosine Phosphorylation and Kinase Activity", J. Biol. Chem., 1992, 267, pgs 13-16.
	C2	Kase et al., "K-252 Compounds, Novel and Potent Inhibitors of Protein Kinase C and Cyclic Nucleotide-Dependent Protein Kinases", Biochem, Biophys. Res. Commun., 1987, 142, pgs 436-440.
	C3	Moody et al., "Synthesis of the Staurosporine Aglycon", J. Org. Chem., 1992, 57, pgs 2105-2114.
	C4	Nakanish et al., "K-252b, c and d, Potent Inhibitors of Protein Kinase C from Microbial Origin", J. Antibiotices", 1986 , <i>34</i> , pgs 1066-1071.
	C5	Shah et al., "Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs", International Journal of Pharmaceutics (Netherlands), 1994, 106, pgs 15-23.
	C6	Yamamoto et al., "Enhanced rectal absorption of itazigrel formulated with polysorbate 80 micelle vehicle in rat: role of co-administered esterase", J. Pharm. Pharmacol., 1994 , <i>46</i> , pgs 608-611.

ł		
Examiner's Signature	Date:	
Examiner 5 Signature	Date.	